Dihexa

Dihexa is a metabolically stabilized, orally active derivative of angiotensin IV, engineered at Washington State University to cross the blood-brain barrier and drive structural plasticity in the hippocampus and cortex. Its mechanism is unlike most nootropics on the market — it isn't a stimulant, it isn't a cholinergic, and it isn't a classical neurotransmitter modulator. It's a growth-factor potentiator, and the effects it produces are built over weeks rather than felt within hours.

HGF / c-Met Positive Modulation#

The core mechanism is positive allosteric modulation of the hepatocyte growth factor (HGF) / c-Met receptor system. Dihexa binds HGF directly with reported picomolar affinity, facilitates HGF dimerization at the c-Met binding interface, and thereby amplifies c-Met autophosphorylation at HGF concentrations that would otherwise be sub-threshold. In practice: it takes the endogenous HGF already circulating in brain tissue and makes it biologically louder.

"Dihexa facilitated HGF dimerization at the c-Met binding site and potentiated c-Met phosphorylation at sub-threshold HGF concentrations, driving robust increases in hippocampal dendritic spine density and synapse formation." — Benoist, C.C. et al. Journal of Pharmacology and Experimental Therapeutics, 2014

Worth flagging for honesty: this originating paper was retracted in April 2025 over image-integrity concerns, and the 2013 McCoy paper carries an Expression of Concern. The HGF-mimetic story has since been reproduced by independent groups (Uribe 2023 in hair cells; Martino 2025 in TBI models), so the mechanism itself is holding up — but the foundational lab's primary data isn't above critique, and you should know that going in.

Synaptogenesis and Dendritic Spine Density#

Downstream of c-Met activation, dihexa engages the PI3K/Akt, MAPK/ERK, and mTOR signaling cascades — the same pathways that govern protein synthesis, dendritic growth, and synapse formation. The practical output in animal work is a measurable increase in dendritic spine density in hippocampal neurons, along with enhanced long-term potentiation (LTP). This is the structural substrate of learning and memory: more spines, more synapses, more wiring available for consolidation.

"Dihexa is a blood-brain barrier-permeable, orally active small molecule that binds with high affinity to HGF and facilitates the HGF/c-Met pathway, supporting synaptogenesis and cognitive function in preclinical models." — Wright, J.W. & Harding, J.W. Journal of Alzheimer's Disease, 2015

For the user, this is why dihexa is a "learning push" compound rather than an acute focus aid. You don't feel it come on. What you notice, if the protocol works for you, is that material learned during the run sticks better and recall feels cleaner a few weeks in. Stacking with a choline source (alpha-GPC 300–600 mg) supplies the cholinergic throughput that benefits from the expanded synaptic substrate.

Procognitive Rescue in Damaged Brains#

Dihexa's most replicated functional endpoint is rescue of cognition in impaired animals — scopolamine-blocked rats, aged rats, and more recently rats subjected to repeated mild traumatic brain injury.

"Oral administration of dihexa at doses of 1.25–2.9 mg/kg reversed scopolamine-induced cognitive deficits and improved performance in aged animals, demonstrating both procognitive and antidementia-like activity." — McCoy, A.T. et al. Journal of Pharmacology and Experimental Therapeutics, 2013

"Oral administration of MM-201 (dihexa) produced a dose-dependent improvement in spatial working memory after repeated mTBI, with robust rescue of performance at the highest dose tested." — Martino, K.A. et al. bioRxiv preprint, 2025

The pattern across studies: the worse the starting cognitive state (aged, cholinergically blocked, concussed), the larger the measurable benefit. This is consistent with what experienced users report — dihexa tends to do more for someone rebuilding from TBI, heavy dissociative use, or age-related decline than for a 25-year-old already operating at baseline.

mTOR-Dependent Cytoprotection#

An independent strand of the mechanism lives downstream in mTOR signaling. Beyond the synaptogenesis story, c-Met activation via dihexa has been shown to protect cells from apoptotic stressors in an mTOR-dependent manner — most clearly demonstrated outside the CNS in sensory hair cells.

"We found that MM-201 (dihexa) protected utricular hair cells from neomycin-induced death in a dose-dependent manner, with efficacy dependent on the mTOR signaling pathway." — Uribe, P.M. et al. Hearing Research, 2023

This matters for two reasons. First, it confirms the HGF/c-Met → mTOR axis is real and reproducible by groups outside the WSU lineage. Second, it's the same pro-survival, pro-growth signaling that makes c-Met a validated oncogenic driver in several cancers — which is the single most important caveat for anyone considering dihexa. Positively modulating c-Met is mechanistically the opposite of what oncology does when treating HGF/c-Met-driven tumors. Active malignancy, a personal history of c-Met-linked cancer (hepatocellular, gastric, NSCLC, renal, glioblastoma), or proliferative retinopathy are hard contraindications, not soft ones.

Why It Works on a Week-Scale, Not an Hour-Scale#

Pulling the threads together: dihexa isn't rearranging neurotransmitter levels, it's rebuilding the physical wiring. Growth-factor signaling → kinase cascades → new protein synthesis → new spines and synapses → better cognitive throughput on the tasks that depend on those circuits. That biology takes 2–4 weeks to accumulate into a subjective effect and 4–8 weeks to plateau, which is why the standard community cycle sits in that 4–8 week window. Running it expecting a stimulant response is the most common way users talk themselves into thinking it doesn't work — and running it continuously for months tends to produce diminishing returns rather than compounding ones.

Common (most users)#

• Headaches — more often the vehicle than the peptide. DMSO-based sublingual preps are the usual culprit. Switch to an oral capsule in MCT or a lipid carrier, and make sure you're hydrated. If it persists on a clean oral vehicle, drop dose by 25–30%.
• Sleep disruption / insomnia — dose AM only. If you're splitting, keep the second dose before 1 PM. Late dosing reliably wrecks sleep onset in a subset of users.
• Anxiety, irritability, emotional lability — expected downstream of broad synaptic remodeling. Usually settles inside the first 7–10 days. If it doesn't, lower the dose rather than pushing through. Running dihexa through an active depressive or chronic-stress state tends to amplify whatever neurological state you're already in.
• Vivid dreams / sleep intensity changes — benign, typically fades after week two.
• Transient "dulling" or brain-fog at onset — paradoxical but common in the first week. Hold dose steady; if it hasn't cleared by day 10, drop 25%.
• Injection-site irritation (SC users) — rotate sites, use a proper co-solvent prep, and keep volumes small. Most users don't need SC — oral is cleaner.

Uncommon (dose-dependent or individual)#

• Tolerance-like dulling with chronic high-dose use — running 30+ mg/day continuously past 6–8 weeks tends to flatten returns or invert them. The fix is a real break, not more compound. Cycle 4–8 weeks on, minimum 4 weeks off.
• Persistent anxiety or hypomania-adjacent states — back off immediately. This is the signal to stop, not to ride out.
• DMSO-specific effects — garlic breath, local dermatitis, skin irritation. Not dihexa's fault but worth knowing if you're running a sublingual prep. Clean skin before application, or switch routes.
• Headache that scales with dose — drop dose rather than adding caffeine or analgesics on top.
• Bloodwork: there's no dihexa-specific panel. If you have any personal cancer history, get appropriate imaging and tumor-marker surveillance baseline and at the end of the cycle — see contraindications below.

Rare but serious#

• Theoretical proliferative / oncogenic risk. This is the one that matters. c-Met is a validated oncogenic driver, and dihexa's proposed mechanism is to positively modulate HGF/c-Met signaling — the exact pathway oncology drugs are designed to inhibit. There is no human long-term safety data. Warning signs to stop and get worked up: new persistent lumps, unexplained weight loss, new GI/pulmonary/urinary symptoms, new persistent headaches with neuro signs. Zero human data doesn't mean zero risk — it means unquantified risk.

"Dihexa facilitated HGF dimerization at the c-Met binding site and potentiated c-Met phosphorylation at sub-threshold HGF concentrations, driving robust increases in hippocampal dendritic spine density and synapse formation." — Benoist et al., JPET 2014 (note: this paper was retracted in April 2025 for image-integrity issues; the HGF/c-Met mechanism has since been independently reproduced)

• Pro-angiogenic pathology flare — HGF is pro-angiogenic. Anyone with proliferative retinopathy, active vascular tumor disease, or other angiogenesis-driven pathology should not run this.
• Unknown interactions stacked with other potent growth-factor agents — stacking dihexa with systemic BPC-157, cerebrolysin, intranasal NGF, or similar is compounding proliferative unknowns. No documented events, but the logic is bad.

Hard contraindications#

• Active malignancy of any kind. Do not run dihexa.
• Personal history of c-Met-driven cancers — hepatocellular carcinoma, gastric cancer, NSCLC, renal cell carcinoma, glioblastoma. Do not run dihexa. Strong family history in these lineages is a stop sign too.
• Proliferative retinopathy or other active angiogenesis-driven pathology.
• Pregnancy and breastfeeding. No data, no rationale, no exceptions.
• Co-administration with other systemic growth-factor or strong synaptogenic agents (systemic BPC-157 at high dose, cerebrolysin, NGF) — avoid stacking. Run them in separate blocks if you want them at all.

Sex-specific and PCT considerations#

Dihexa is non-hormonal. The dose range, side-effect profile, and cycling logic are the same for men and women — no virilization concern, no HPTA suppression, no PCT required. The only sex-specific note is pregnancy and breastfeeding: avoid absolutely, no data exists and the mechanism (pro-synaptogenic, pro-angiogenic in a developing organism) is not one you want to gamble on. Women planning conception in the near term should finish the cycle and clear before trying.

"Oral administration of dihexa at doses of 1.25–2.9 mg/kg reversed scopolamine-induced cognitive deficits and improved performance in aged animals, demonstrating both procognitive and antidementia-like activity." — McCoy et al., JPET 2013 (Expression of Concern issued 2021)

Bottom line: at community doses for 4–8 week blocks, most users tolerate dihexa well, and the acute side-effect profile is mild and manageable. The real unknown is the long-tail oncogenic question, which has no human dataset behind it. That's why the community runs short cycles with real breaks and why anyone with a meaningful cancer history should pass on this compound, not negotiate with it.